Ken Griffin Pharvaris N.V. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$15.67 - $24.59 $3.51 Million - $5.5 Million
-223,833 Reduced 93.93%
14,472 $272,000
Q1 2024

May 15, 2024
BUY
$21.26 - $32.07 $2.06 Million - $3.11 Million
96,847 Added 68.46%
238,305 $5.51 Million
Q4 2023

Feb 14, 2024
BUY
$15.2 - $28.05 $2.15 Million - $3.97 Million
141,458 New
141,458 $3.97 Million

Others Institutions Holding PHVS

# of Institutions
51
Shares Held
39.6M
Call Options Held
0
Put Options Held
0
View Full List

About Pharvaris N.V.

PHVS Quotes by TradingView
  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email